For an animated presentation of ProCord, please click here.

---

ProCord - Spinal Cord Injury treatment
ProCord is an autologous activated macrophage therapy, for the treatment of patients with acute complete spinal cord injury.

Following injury, a type of white blood cell, called a macrophage, is quickly mobilized, and starts to remove cell debris. These macrophages then start to secrete growth factors that promote a controlled inflammatory reaction, the initial phase of the wound healing process. While this process normally occurs in most tissues, including peripheral nerves, it does not occur in the central nervous system (CNS), including the spinal cord. Preclinical studies led by Prof. Michal Schwartz of the Weizmann Institute of Science have shown that specially-treated macrophages promote recovery from spinal cord injury (SCI). Based on these findings, Proneuron is developing ProCord as a clinical product to treat spinal cord injury patients. ProCord consists of macrophages isolated from the patient's own blood, co-incubated with the patient's skin in a proprietary process and then injected directly into the patient's injured spinal cord. For the Scientific articles please click here.

Proneuron is currently engaged in an international, multicenter, randomized-control, Phase II trial of ProCord as a treatment for spinal cord injuries. Further details.